FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults
Posted:
The Food and Drug Administration expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
Upcoming Luscii - an OMRON Healthcare service webinar: Enabling Exceptional At-home Care for Children
Date: 12 September 2024, 10:30 – 11.15am
They explore the opportunities of technology-enabled paediatric care.
Sign up here.
S-PRO has become a member of SwissICT, the largest professional association for the Information and Communications Technology industry in Switzerland. Read the full article here.
Attendees
Sponsors and
Exhibitors
Agenda
Webinars
Contact us